The NIH Exploratory Trials in Parkinson's Disease (NET-PD) program was established to facilitate the development of therapies to slow the progression of this chronic neurodegenerative disease. This network effectively executed futility studies of candidate therapies, which identified creatine as a having therapeutic potential. A subsequent Phase 3 efficacy trial, known as Long-term Study 1 (LS1) was designed and is being executed to evaluate the efficacy of creatine in slowing clinical decline in Parkinson's Disease (PD). LS1 is currently operational and has successfully met recruitment goals. Participants are being followed for a minimum of 5 years and maximum of 8 years. As a result, the final study visits will occur between June 2014 and May 2015. The current application requests funds to carry out Clinical Coordination Center activities through the completion of the NET-PD trials. These activities are guided by the following specific aims.
Specific Aim 1 is to complete follow-up and enhance retention of enrolled participants in LS1 in order to test the primary hypothesis that daily administration of creatine (10gm/day) is more effective than placebo in slowing clinical decline in PD against the background of dopaminergic therapy and best PD care.
Specific Aim 2 is to perform secondary analyses to evaluate the efficacy of creatine on individual PD clinical measures between baseline and the final follow-up visit that encompasses 5-8 years of study participation, as well as analyses of overall safety and tolerability.
Specific Aim 3 is to continue to operate a Clinical Coordination Center for the completion of NET-PD studies, which involves (a) maintenance of study protocols, (b) Clinical Site oversight and training, (c) maintenance of quality and regulatory standards, (d) logistical oversight of experimental treatment distribution to Clinical Sites, (e) receipt and management of all clinical trial data, (f) close out the database and transfer to the Statistical Coordination Ceter for analysis, (g) participation in the analysis plans, interpretation and reporting of the trial reults, and (h) assisting the Statistical Coordinating Center in documenting and archiving the data in a publicly available database.
Specific Aim 4 is to maintain an administrative structure that allows close collaboration with the Statistical Coordination Center, the Clinical Sites, NINDS Scientific Program personnel, the NINDS Data and Safety Monitoring Board and the NINDS Oversight Committee. Successful completion of these aims will achieve the goal of the NET-PD program to establish an innovative, evidence-based process by which potential therapies are selected and tested for slowing of PD progression.
The accumulated disability that PD causes is a major source of diminished quality of life and increased health care costs. Despite the advances in our understanding of the pathophysiology in PD, there are no current therapies that slow the inexorable clinical decline. LS1 will help to determine if creatine can slow clinical decline and provide better information on the course of early PD than is currently available. Disclaimer: Please note that the following critiques were prepared by the reviewers prior to the Study Section meeting and are provided in an essentially unedited form. While there is opportunity for the reviewers to update or revise their written evaluation, based upon the group's discussion, there is no guarantee that individual critiques have been updated subsequent to the discussion at the meeting. Therefore, the critiques may not fully reflect the final opinions of th individual reviewers at the close of group discussion or the final majority opinion of the group. Thus the Resume and Summary of Discussion is the final word on what the reviewers actually considered critical at the meeting.
|Chen, Yong; Luo, Sheng; Chu, Haitao et al. (2014) An Empirical Bayes Method for Multivariate Meta-analysis with an Application in Clinical Trials. Commun Stat Theory Methods 43:3536-3551|
|Luo, Sheng (2014) A Bayesian approach to joint analysis of multivariate longitudinal data and parametric accelerated failure time. Stat Med 33:580-94|
|Constantinescu, Radu; Elm, Jordan; Auinger, Peggy et al. (2014) Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial. Mov Disord 29:263-5|
|Getman, Michael; England, Samantha J; Malik, Jeffery et al. (2014) Extensively self-renewing erythroblasts derived from transgenic ?-yac mice is a novel model system for studying globin switching and erythroid maturation. Exp Hematol 42:536-46.e8|
|Parashos, Sotirios A; Luo, Sheng; Biglan, Kevin M et al. (2014) Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol 71:710-6|
|Luo, Sheng; Chen, Yong; Su, Xiao et al. (2014) mmeta: An R Package for Multivariate Meta-Analysis. J Stat Softw 56:11|
|Chen, Yong; Luo, Sheng; Chu, Haitao et al. (2013) Bayesian inference on risk differences: an application to multivariate meta-analysis of adverse events in clinical trials. Stat Biopharm Res 5:142-155|
|Luo, Sheng; Ma, Junsheng; Kieburtz, Karl D (2013) Robust Bayesian inference for multivariate longitudinal data by using normal/independent distributions. Stat Med 32:3812-28|
|Luo, Sheng; Yi, Min; Huang, Xuelin et al. (2013) A Bayesian model for misclassified binary outcomes and correlated survival data with applications to breast cancer. Stat Med 32:2320-34|
|Luo, Sheng (2013) Joint analysis of stochastic processes with application to smoking patterns and insomnia. Stat Med 32:5133-44|
Showing the most recent 10 out of 31 publications